ReviewNature reviews. Cardiology2009
Antiplatelet drug 'resistance'. Part 1: mechanisms and clinical measurements.
Review in Nature reviews. Cardiology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 96 citations in OpenAlex.
- Effect of palm-based tocotrienols and tocopherol mixture supplementation on platelet aggregation in subjects with metabolic syndrome: a randomised controlled trial.Scientific reports · 2017Trial
- PAR-1 antagonist vorapaxar favorably improves global thrombotic status in patients with coronary disease.Journal of thrombosis and thrombolysis · 2014Trial
- Safety and effectiveness of low dosing of double antiplatelet therapy during long-term left ventricular support with the INCOR system.Journal of artificial organs : the official journal of the Japanese Society for Artificial Organs · 2010Trial
- Purification and Characterization of Novel Collagen Peptides fromFoods (Basel, Switzerland) · 2026Article
- High-throughput combinatorial screening of antiplatelet drugs for personalized medicine.Microsystems & nanoengineering · 2026Article
- Prevention of acute thrombosis with vascular endothelium antioxidative nanoscavenger.Nature nanotechnology · 2025Article
- NebulaPlate: a droplet microfluidic platform to analyze platelet aggregation.Journal of nanobiotechnology · 2025Article
- Thrombus aspiration in primary percutaneous coronary intervention in acute ST-elevation myocardial infarction patients with high thrombus burden: one-year outcomes in a tertiary healthcare center in Ho Chi Minh City.The Egyptian heart journal : (EHJ) : official bulletin of the Egyptian Society of Cardiology · 2024Article
- Insights into platelet pharmacology from a cryo-EM structure of the ABCC4 transporter.Nature cardiovascular research · 2023Article
- Impacts of Commonly Used Edible Plants on the Modulation of Platelet Function.International journal of molecular sciences · 2022Review
- Microfluidic chip grafted with integrin tension sensors for evaluating the effects of flowing shear stress and ROCK inhibitor on platelets.Lab on a chip · 2021Article
- Point-of-care platelet function tests: relevance to arterial thrombosis and opportunities for improvement.Journal of thrombosis and thrombolysis · 2021Review
- Medication History versus Point-of-Care Platelet Activity Testing in Patients with Intracerebral Hemorrhage.Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association · 2018Observational
- Prevalence and risk factors of clopidogrel non-response among Saudi patients undergoing coronary angiography.Saudi medical journal · 2016Article
- The Effect of Xuefuzhuyu Oral Liquid on Aspirin Resistance and Its Association with rs5911, rs5787, and rs3842788 Gene Polymorphisms.Evidence-based complementary and alternative medicine : eCAM · 2015Article
- Projected inhibition of platelet aggregation with ticagrelor twice daily vs. clopidogrel once daily based on patient adherence data (the TWICE project).British journal of clinical pharmacology · 2014Article
- A case of three consecutive events of acute myocardial infarctions in three different vessels.Korean circulation journal · 2013Article
- Article
- Aspirin treatment failure and the risk of recurrent stroke and death among patients with ischemic stroke.Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association · 2013Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Antiplatelet drug therapy has become one of the cornerstones of treatment for patients with cardiovascular disease. Large clinical trials have shown that antiplatelet medications have important clinical benefits and prevent adverse outcomes in patients with coronary artery disease. Recurrent adverse cardiovascular events still occur in a substantial proportion of patients on standard dual antiplatelet therapy, however, which has been attributed to nonresponsiveness to this treatment. Both pharmacological and pharmacokinetic mechanisms are involved in variability in responsiveness to antiplatelet agents, and include drug bioavailability, medication noncompliance, drug-drug interactions, cytochrome P450 activity, and genetic polymorphisms. Numerous observational studies have consistently shown an association between antiplatelet drug nonresponsiveness and adverse clinical outcomes. However, these studies are limited by varying antiplatelet drug dosing regimens, heterogeneous laboratory assessments for ex vivo platelet function, and wide interindividual variation in platelet responses. Only within the last 2 years have randomized clinical trials indicated that increased dosing with antiplatelet drugs could reduce adverse clinical outcomes. Nonetheless, large clinical trials with standardized laboratory methods and well-defined protocols are needed that will definitively determine the association between antiplatelet drug nonresponsiveness and clinical events, and establish therapeutic strategies to overcome blunted antiplatelet effects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.